ANG1005 in Leptomeningeal Disease From Breast Cancer
- Conditions
- HER2-negative Breast CancerLeptomeningeal CarcinomatosisLeptomeningeal MetastasesBrain Metastases
- Interventions
- Drug: Physician's Best Choice
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 150
- Registration Number
- NCT03613181
Expanded Access to ANG1005 for Individual Patients
- Conditions
- Breast Cancer With Recurrent Brain MetastasesAnaplastic OligodendrogliomaLeptomeningeal CarcinomatosisAnaplastic Astrocytoma
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Angiochem Inc
- Registration Number
- NCT02755987
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸Univeristy of Texas Health Science Center in San Antonio, San Antonio, Texas, United States
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 72
- Registration Number
- NCT02048059
- Locations
- 🇺🇸
University of California - LAC Medical Center, Los Angeles, California, United States
🇺🇸GRU Cancer Center - Georgia Regents University, Augusta, Georgia, United States
🇺🇸University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States
ANG1005 in Patients With Recurrent High-Grade Glioma
- Conditions
- GliomaGlioblastomaBrain Tumor, Recurrent
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 73
- Registration Number
- NCT01967810
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
- Conditions
- Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 16
- Registration Number
- NCT01497665
- Locations
- 🇺🇸
Northwestern Univ., Chicago, Illinois, United States
🇺🇸Univ. of California San Diego, La Jolla, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
- Conditions
- Breast CancerBrain Metastases
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 85
- Registration Number
- NCT01480583
- Locations
- 🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸NCI, Rockville, Maryland, United States
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 63
- Registration Number
- NCT00539344
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, United States
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
- Conditions
- Advanced Solid Tumors With and Without Brain Metastases
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 56
- Registration Number
- NCT00539383
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UT Health Science Center, Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States